Business
Investor Webinar
Investor Webinar.
About this update from Aptamer Group Plc
31 July 2025 Aptamer Group plc ("Aptamer", the "Company" or the "Group") Investor Webinar Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, announces that Dr Arron Tolley, Chief Executive Officer, and Andrew Rapson, Chief Financial Officer, will be hosting an investor webinar on Thursday, 7 August 2025, at 6:00 p.m. (BST). The webinar will principally cover the Company's recent progress, focusing on developments highlighted in the Trading Update released by the Company at 07:00 today. There will be a Q&A session for investors after the presentation, and questions can be submitted pre-event as part of the registration process. The webinar is open to shareholders and other interested parties who can register for the event by using the following link: https://www.turnerpope.com/register/ The webinar will be chaired by experienced news and corporate events presenter Katie Pilbeam ( www.katiepilbeam.com ) and hosted by the Company's broker, Turner Pope Investments. - Ends - For further information, please contact: Aptamer Group plc Dr Arron Tolley, Chief Executive Officer +44 (0) 1904 217 404 SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat +44 (0) 20 3368 3550 Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker +44 (0) 20 3657 0050 Northstar Communications Limited - Investor Relations Sarah Hollins +44 (0) 113 730 3896 About Aptamer Group Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies. Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue. Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK. To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/